糖尿并不总是由糖尿病引起的。
Glucosuria Is Not Always Due to Diabetes.
作者信息
Lewis Meghan, Dass Bhagwan
机构信息
is a Resident Physician, and is a Staff Physician, both at Eglin Air Force Base in Florida. Bhagwan Dass is an Associate Professor at the University of Florida in Gainesville.
出版信息
Fed Pract. 2021 Feb;38(2):92-95. doi: 10.12788/fp.0091.
Abstract
Further study of the long-term implications and follow-up is needed on SGLT2 mutation, an uncommon cause of glucosuria that mimics the effect of SGLT2 inhibitors, including the possible development of further renal disease, type 2 diabetes mellitus, and cardiovascular disease.
摘要
需要对SGLT2突变进行进一步研究，以了解其长期影响并进行随访。SGLT2突变是一种罕见的糖尿病因，可模拟SGLT2抑制剂的作用，包括可能进一步发展为肾脏疾病、2型糖尿病和心血管疾病。
相似文献
1
Glucosuria Is Not Always Due to Diabetes.糖尿并不总是由糖尿病引起的。
Fed Pract. 2021 Feb;38(2):92-95. doi: 10.12788/fp.0091.
2
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.SGLT2 抑制剂在心血管疾病和肾功能障碍中的保护作用机制。
Curr Top Med Chem. 2019;19(20):1818-1849. doi: 10.2174/1568026619666190828161409.
3
Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2).由钠葡萄糖协同转运蛋白（SGLT2）突变引起的常染色体隐性肾性糖尿。
Hum Genet. 2002 Dec;111(6):544-7. doi: 10.1007/s00439-002-0820-5. Epub 2002 Sep 27.
4
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.家族性肾性糖尿和 SGLT2：从孟德尔性状到治疗靶点。
Clin J Am Soc Nephrol. 2010 Jan;5(1):133-41. doi: 10.2215/CJN.04010609. Epub 2009 Nov 5.
5
Molecular analysis of the SGLT2 gene in patients with renal glucosuria.肾性糖尿患者SGLT2基因的分子分析。
J Am Soc Nephrol. 2003 Nov;14(11):2873-82. doi: 10.1097/01.asn.0000092790.89332.d2.
6
Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.与钠-葡萄糖协同转运蛋白2抑制剂卡格列净相关的伴有长期糖尿的正常血糖性糖尿病酮症酸中毒
J Investig Med High Impact Case Rep. 2017 Jun 8;5(2):2324709617712736. doi: 10.1177/2324709617712736. eCollection 2017 Apr-Jun.
7
Development of SGLT1 and SGLT2 inhibitors.SGLT1 和 SGLT2 抑制剂的研发。
Diabetologia. 2018 Oct;61(10):2079-2086. doi: 10.1007/s00125-018-4654-7. Epub 2018 Aug 22.
8
The renal effects of SGLT2 inhibitors and a mini-review of the literature.钠-葡萄糖协同转运蛋白2抑制剂的肾脏效应及文献综述
Ther Adv Endocrinol Metab. 2016 Dec;7(5-6):212-228. doi: 10.1177/2042018816676239. Epub 2016 Nov 11.
9
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.正在研发中的用于治疗 2 型糖尿病的钠-葡萄糖协同转运蛋白 2 抑制剂的区分。
Expert Opin Investig Drugs. 2013 Apr;22(4):463-86. doi: 10.1517/13543784.2013.774372. Epub 2013 Mar 1.
10
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.靶向肾脏葡萄糖重吸收以治疗高血糖：SGLT2抑制剂的多效性作用
Diabetologia. 2017 Feb;60(2):215-225. doi: 10.1007/s00125-016-4157-3. Epub 2016 Nov 22.
本文引用的文献
1
SGLT2 inhibitors for primary prevention of cardiovascular events.用于心血管事件一级预防的钠-葡萄糖协同转运蛋白2抑制剂
J Diabetes. 2020 Jan;12(1):5-7. doi: 10.1111/1753-0407.13004. Epub 2019 Nov 21.
2
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.钠-葡萄糖协同转运蛋白 2 抑制剂的安全性。
Am J Cardiol. 2019 Dec 15;124 Suppl 1:S45-S52. doi: 10.1016/j.amjcard.2019.10.029.
3
A Case of Isolated Glycosuria Mediated by an Gene Mutation and Characterized by Postprandial Heavy Glycosuria Without Salt Wasting.一例由基因突变介导的孤立性糖尿，其特征为餐后重度糖尿且无盐耗损。
Electrolyte Blood Press. 2016 Dec;14(2):35-37. doi: 10.5049/EBP.2016.14.2.35. Epub 2016 Dec 31.
4
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂治疗糖尿病的最新进展
Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):73-79. doi: 10.1097/MED.0000000000000311.
5
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
6
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
7
Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.恩格列净：一种用于治疗2型糖尿病的新型钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂。
Drugs Context. 2014 Jun 11;3:212262. doi: 10.7573/dic.212262. eCollection 2014.
8
Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion.另外21例家族性肾性糖尿：无基因异质性、私人突变高患病率及容量耗竭的进一步证据
Nephrol Dial Transplant. 2008 Dec;23(12):3874-9. doi: 10.1093/ndt/gfn386. Epub 2008 Jul 12.
9
Renal glucosuria due to SGLT2 mutations.由SGLT2基因突变导致的肾性糖尿。
Mol Genet Metab. 2004 May;82(1):56-8. doi: 10.1016/j.ymgme.2004.01.018.
Zotero 插件